Merck Shares Advances in MS Portfolio with Key Efficacy and Safety Data at AAN 2022

New Phase II data show evobrutinib sustained low annualized relapse rates (ARRs) and had no new safety signals at 2.5 years the longest follow-up of any Bruton's tyrosine kinase inhibitor in multiple

Related Keywords

United States ,Norway ,Australia ,Iceland ,Sheraton ,British Columbia ,Canada ,United Kingdom ,Sweden ,Finland ,Liechtenstein ,South Korea ,Barlo ,Nordrhein Westfalen ,Germany ,Coray ,American ,Merck Aanam Msinsideout ,Suzart Woischnik ,Jan Klatt ,Mackie ,Neurology Center ,Linkedin ,Barlo Ms Centre ,Additional Company ,Merck Press ,European Commission ,Ms Lifelines Patient Support Program ,European Union ,Serono ,American Academy Of Neurology ,New Phase ,Annual Meeting ,Senior Vice President ,Development Unit Neurology Immunology ,Therapeutic Update ,Ann Bass ,Medical Director ,San Antonio ,Grand Ballroom ,Sheraton Grand ,Healthcare Business ,Oral Presentations ,Tyrosine Kinase Inhibitor ,Slowly Expanding Lesions ,Emerging Imaging Marker ,Chronic Tissue Loss ,Multiple Sclerosis ,Profile Characterization ,Rheumatoid Arthritis ,Systemic Lupus Erythematosus ,Poster Presentations ,Relapsing Multiple Sclerosis Over ,Open Label Extension ,Myeloid Cells ,Basic Science ,Patients With ,Two Phase ,Cladribine Tablets ,Comparative Effectiveness ,Practice Decision Making ,Highly Active Relapsing Multiple Sclerosis ,Mavenclad Real ,Trials Therapeutics ,Disease Modifying Therapy ,Interim Baseline And Safety Review ,Patients Receiving Subcutaneous Interferon ,Subcutaneous Interferon ,With Particular Reference ,Respiratory Viral ,Register Based Drug Utilisation Study ,Product Specific Poster Presentations ,Experiences During ,Individuals Enrolled ,Lines Patient Support Program ,Multiple Sclerosis Enrolled ,Cladribine Tablets Treating ,Oral Cladribine ,Oral Cladribine Added ,Patients With Active Relapsing Disease ,Merck Press Releases ,Merck ,Hares ,Advances ,Portfolio ,Efficacy ,Safety ,Data ,022 ,